HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
02. November 2022 16:01 ET
|
HiberCell, Inc.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
24. Mai 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced...
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
28. April 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutic candidates to address therapeutic resistance, cancer relapse and metastasis,...
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
03. März 2022 08:00 ET
|
HiberCell, Inc.
In-person presentation taking place Wednesday, March 9, in the session beginning at 5:00pm MSTPresentation in Trained Immunity in Disease Treatment Session at Keystone Symposia in Banff, AB,...
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
24. Februar 2022 08:00 ET
|
HiberCell, Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, has initiated...
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer
14. Dezember 2021 08:00 ET
|
HiberCell
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
07. Dezember 2021 10:58 ET
|
HiberCell
Open-label phase 2 clinical trial is actively recruiting new patients and opening new sitesResults to be presented in a poster session at SABCS 2021 on December 8, 2021NEW YORK, Dec. 07, 2021 (GLOBE...
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer
30. September 2021 08:00 ET
|
HiberCell
Expands Board of Directors with Appointment of Cindy Jacobs, PhD, MD NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat...
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
08. September 2021 08:00 ET
|
HiberCell
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today that the U.S. Food and...
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
16. August 2021 08:00 ET
|
HiberCell
NEW YORK and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today the...